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Abstract 
Review on ELF4, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: ELFR, MEF 
HGNC (Hugo): ELF4 
Location: Xq26.1 
Local order: The ELF4 gene maps on chomosome 
X at position +1805468958720.00 (interpolated), at 
Xq26 according to Entrez Gene. In AceView, it 
covers 46,69 kb, from 129244687 to 129197994, on 




The gene encompasses 45 kb of DNA; 9 exons.  
The ELF4 gene contains 12 distinct gt-ag introns. 
Transcription produces 5 alternatively spliced 
mRNAs.  
There are 2 probable alternative promoters, 2 non 
overlapping alternative last exons and 2 validated 
alternative polyadenylation sites.  
The mRNAs appear to differ by truncation of the 3' 
end, presence or absence of 3 cassette exons, 
overlapping exons with different boundaries, 
splicing versus retention of 2 introns. 
 
 
The ELF4 gene is located on the X-chromosome (Xq26) and is transcribed from telomere to centromere. The ELF4 gene 
contains 8 coding exons and 1 non-coding exon. 
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The ELF4 protein contains the following domains: (A) transactivation domain, (B) AML1 interacting domain, (C) ETS domain, (D) 
serine/threonine rich region and (E) proline rich region. 
 
Transcription 
4190 bp mRNA; 1991 bp open reading frame. 
Pseudogene 
No observed pseudogenes. 
Protein 
Description 
663 amino acids; 70730 Da protein; numerous 
posttranslational modifications: phosphorylation, 
sumoylation and ubiquitination (Miyazaki et al., 
2001; Liu et al., 2006; Suico et al., 2006). ELF4 
contains, from N-term to C-term, transactivation 
domain (53-86), AML1 interacting domain (87-
206), ETS domain (207-291), serine/threonine rich 
region (306-347) and proline rich region (477-517) 
(Miyazaki et al., 1996; Mao et al., 1999; Suico et 
al., 2002; Lacorazza and Nimer, 2003). 
Expression 
Abundantly expressed in the placenta and in a 
variety of myeloid leukemia cell lines. Moderate 
levels of expression in heart, lung, spleen, thymus, 
peripheral blood lymphocytes, ovary and colon. 
Lower levels of expression in Jurkat T-cells and 
other T-cell lines and no expression in brain 
(Lacorazza and Nimer, 2003). 
Localisation 
Nucleus, PML body. Accumulation into PML 
nuclear bodies is mediated by PML (Suico et al., 
2004a; Suico et al., 2004b). 
Function 
ELF4 is a member of the ETS family of 
transcription factors (TF) with transcription 
activating properties (Lacorazza and Nimer, 2003). 
ELF4 binds to DNA sequences containing the 
consensus 5'-WGGA-3' and transactivates 
promoters of the hematopoietic growth factor genes 
CSF2, IL3, IL8, and of the bovine lysozyme gene 
(Miyazaki et al., 1996; Mao et al., 1999; Hedvat et 
al., 2004; Suico et al., 2004). ELF4 acts 
synergistically with RUNX1 to transactivate the 
IL3 promoter (Mao et al., 1999).  
It also transactivates the PRF1 promoter in natural 
killer (NK) cells (Lacorazza et al., 2002).  
ELF4 has important molecular functions, including 
protein binding, transcription activator activity, 
sequence-specific DNA binding, transcription 
factor activity. ELF4 interacts with multiple 
proteins, including Cyclin A/CDK2 kinase 
complex, FBXO4, FBXO7, PML, RUNX1, SKP2 
and UBB (Miyazaki et al., 1996; Mao et al., 1999; 
Miyazaki et al., 2001; Liu et al., 2006; Suico et al., 
2006). 
 
ELF4 interacts with multiple proteins and plays important role in development and oncogenesis. 
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ELF4 has been implicated in widely divergent 
physiological and pathological processes (such as 
development and oncogenesis).  
ELF4 plays an important role in the development 
and function of NK and NK T-cells and in innate 
immunity (Lacorazza et al., 2002).  
It controls the proliferation and homing of CD8+ T-
cells via the Kruppel-like factors KLF4 and KLF2 
(Yamada et al., 2009; Yamada et al., 2010).  
ELF4 regulates hematopoietic stem cell quiescence 
and self-renewal (Lacorazza et al., 2006; Liu et al., 
2009). ELF4 also regulates self-renewal of brain-
tumor stem cells (Bazzoli et al., 2012).  
In addition, ELF4 plays an important role in 
osteogenic differentiation and bone development 
(Kim et al., 2007; Seul et al., 2011; Baek et al., 
2012).  
It mediates DNA damage response (Morales et al., 
2008; Sashida et al., 2011).  
ELF4 controls cell senescence in a p53-dependent 
manner and can also promote cellular 
transformation through inhibition of the p16 
pathway as well (Sashida et al., 2009).  
ELF4, a member of the ETS transcription factors, 
can function as an oncogene in murine cancer 
models and is overexpressed in various human 
cancers (Lacorazza and Nimer, 2003; Sashida et al., 
2010).  
In addition to its oncogenic potential, ELF4 has 
been proposed to be a candidate tumor suppressor 
gene on the X chromosome (Seki et al., 2002). 
Homology 
The transcription factor ELF4 belongs to the ETS 
family of transcription factors, named after the E26 
(E twenty six) leukemogenic chicken virus which 
contains a gag-myb-ets fusion.  
These proteins are characterized by the presence of 
the ETS domain (a conserved 84 amino acid 
domain) that binds to a DNA consensus sequence 
containing a GGAA central core via a winged 
helix-turn-helix motif.  
Based on the homology of the ETS domain, these 
proteins have been classified in different 
subfamilies (e.g., Elf, Spi, and Yan).  
The ETS domain is highly conserved among family 
members with the greatest homology of ELF4 with 
other proteins in the Elf subfamily, which also 
includes ELF1, NERF1a, and NERF1b. ELF4 does 
not contain an HLH or pointed protein-protein 
interaction domain, which is present in members of 
the ETS, ERG, GABP, and Yan subfamilies 
(Lacorazza and Nimer, 2003). 
Mutations 
Note 
No known mutations. Fused in hepatocellular 
carcinoma with the BCORL1 gene. 
Implicated in 
Acute myeloid leukemia 
Disease 
Acute myeloid leukemia (AML) is the most 
common acute leukemia in adults. It usually occurs 
around age 60 with no identifiable cause and it 
carries a very poor prognosis, with most patients 
living less than 18 months. AML is a devastating 
illness with over 13000 new diagnoses and 10000 
patients dying annually in the United States. 
Although select molecular subpopulations of 
patients are long-term survivors, the overall five-
year survival for adults is only 25%. ETS proteins 
(such as PU.1, Fli-1 and ETS-1) have been shown 
to play important roles in normal and abnormal 
hematopoiesis (Lacorazza and Nimer, 2003). ELF1 
and ELF4 were expressed in all AML samples, 
whereas NERF was not. The relative expression of 
ELF4, but not ELF1, was significantly lower 
(P<0.0001) in AML with t(8;21) and t(15;17) 
compared with AML with normal karyotype 
(Fukushima et al., 2003; Ando et al., 2013). 
Prognosis 
The low relative expression of ELF4, might be part 
of a gene expression profile characterizing AML 
with a good prognosis (Fukushima et al., 2003; 
Ando et al., 2013). 
Cytogenetics 
A chromosomal translocation has been reported in 
AML, t(X;21)(q25-26;q22), that generates a fusion 
transcript between two ETS family members, ELF4 
(at Xq26) and ERG (at 21q22). The translocation 
occurs within intron 1 of ERG isoform 1 (ERG-1) 
and intron 2 of ELF4 resulting in an in-frame fusion 
joining exon 2 from ELF4 with exon 2 of ERG 
(Moore et al., 2006). 
Hybrid/Mutated gene 
ELF4-ERG. The fusion sequence includes exon 2 
of ELF4 and exon 2 of ERG1, with the breakpoint 
occurring after exon 2 in ELF4 (intron 2) and 
before exon 2 of ERG1 (intron 1) (Moore et al., 
2006). 
Abnormal protein 
ELF4-ERG (495 amino acids). 
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Horizontal lines represent amino acid residues for ELF4 and ERG-1. Numbers above each line indicate the number of amino 
acids at the corresponding position. Boxes below indicate locations of the conserved domains within both protein sequences. 
The predicted fusion protein would include the first 25 amino acid residues from ELF4 encoded by exon 2 and the last 470 amino 
acid residues encoded by ERG exons 2-10 resulting in a protein of 495 amino acids. The conserved SAM-PNT and ETS 
domains from ERG would be included in the fusion while the ETS domain from ELF4 would be excluded. 
Oncogenesis 
ERG has been associated with other fusion partners, 
specifically FUS and EWSR1, and implicated in 
both AML and Ewing's sarcoma. The ELF4-ERG 
fusion suggests a new role for ELF4 in 
leukemogenesis and human cancer (Moore et al., 
2006), as it provides a strong promoter to express 
ERG.  
In addition, wild-type nucleophosmin (NPM1) 
inhibits the DNA binding and transcriptional 
activity of ELF4 on the HDM2 promoter, while a 
common, leukemia-associated NPM1 mutant 
protein (Mt-NPM1) enhances these activities of 
ELF4 (Ando et al., 2013). Moreover, clinical 
leukemia samples with NPM1 mutations have 
higher human MDM2 (HDM2) mRNA expression. 
These data suggest that enhanced HDM2 
expression induced by mutant NPM1 may have a 




Ovarian cancer is the seventh most common cancer 
in women worldwide and the second leading cause 
of death among the gynecological malignancies. 
ELF4 is expressed in a significant proportion of 
ovarian carcinomas, and in the CAOV3 and 
SKOV3 ovarian cancer cell lines, but not in normal 
ovarian surface epithelium (Yao et al., 2007). 
Prognosis 
High levels of ELF4 expression in ovarian cancer 
are associated with a poor prognosis (Yao et al., 
2007). 
Oncogenesis 
Manipulating MEF levels in ovarian cancer cell 
lines alters their behavior; reducing ELF4 levels, 
using short hairpin RNA expressing vectors, 
significantly inhibited the proliferation of SKOV3 
and CAOV3 cells in culture, and impaired the 
anchorage-independent growth of CAOV3 cells. 
Overexpression of ELF4 in SKOV3 cells 
significantly increased their growth rate, enhanced 
colony formation in soft agar and promoted tumor 
formation in nude mice. The oncogenic activity of 
MEF was further shown by the ability of ELF4 to 
transform NIH3T3 cells, and induce their tumor 
formation in nude mice (Yao et al., 2007). Thus, 
ELF4 is an important regulator of the tumorigenic 
properties of ovarian cancer cells and could be used 




Malignant gliomas represent the most prevalent 
primary brain tumor in adults and inevitably have a 
poor prognosis. Despite the implementation of new 
therapeutic strategies, the median survival of 
patients with glioblastoma multiforme (GBM), the 
most aggressive glioma variant, is only 14-16 
months and these tumors remain rapidly and 
uniformly fatal. High-grade gliomas are composed 
of a heterogeneous population of cells that include 
many with stem-cell-like properties. The 
acquisition of stem-like traits might contribute to 
glioma initiation, growth, and recurrence. ELF4 is 
highly expressed in both human and mouse 
glioblastomas and its absence impairs 
gliomagenesis in a PDGF-driven glioma mouse 
model (Bazzoli et al., 2012). 
Prognosis 
High levels of ELF4 expression in gliomas are 
associated with a poor prognosis (Bazzoli et al., 
2012). 
Oncogenesis 
Modulation of ELF4 levels in both mouse neural 
stem cells and human glioblastoma cells has a 
significant impact on neurosphere formation. Thus, 
ELF4 is a gatekeeper gene that promotes stemness 
in the pathogenesis of gliomas (Bazzoli et al., 
2012). 
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